The dual-reciprocating drill (DRD) is a low-mass alternative to traditional drilling techniques biologically inspired by the wood wasp ovipositor, which is used to drill into wood in order to lay its eggs. The DRD reciprocates two halves lined with backwards-facing teeth, enabling it to generate traction forces that reduce the required overhead penetration force. While previous research has focused on experimental testing of the drill's operational and design parameters, numerical simulation techniques are being developed to allow the rapid testing of multiple designs, complementing and informing experimental testing campaigns. The latest DRD design iteration integrated a novel internal actuation mechanism and demonstrated the benefits of adding controlled lateral movements. This paper presents an exploration of how bit morphology affects drilling performance and a preliminary study of discrete element method (DEM) simulations for modelling DRD interactions in regolith. These have shown how regolith grain size and microscopic behaviour significantly affects the performance of different drill designs, and demonstrated how customisable drills can exploit the properties of various substrates. Two system prototypes are also being developed for the DRD's third generation, each utilising novel actuation and sampling mechanisms. A final drill design will then be deployed from a planetary rover and perform the first DRD drilling and sampling operation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7558545 | PMC |
http://dx.doi.org/10.3390/biomimetics5030038 | DOI Listing |
J Gastroenterol
January 2025
Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Mitaka, Japan.
Background: Despite the availability of several biologics for ulcerative colitis (UC), there remains a critical need to identify first-line treatment biologics. The superiority of infliximab (IFX) over vedolizumab (VED) and ustekinumab (UST) was evaluated as initial UC treatments in patients with biologic-naïve UC.
Methods: This multicenter, randomized control trial was conducted across 20 Japanese medical institutions.
Int Urogynecol J
January 2025
School of Nursing, Binzhou Medical University, Bincheng District, No. 522, Huanghe Third Road, Binzhou, Shandong, China.
Introduction And Hypothesis: This study aims to develop a postpartum stress urinary incontinence (PPSUI) risk prediction model based on an updated definition of PPSUI, using machine learning algorithms. The goal is to identify the best model for early clinical screening to improve screening accuracy and optimize clinical management strategies.
Methods: This prospective study collected data from 1208 postpartum women, with the dataset randomly divided into training and testing sets (8:2).
Microbiology (Reading)
January 2025
Instituto de Microbiologa, Colegio de Ciencias Biolgicas y Ambientales, Universidad San Francisco de Quito, Quito, Ecuador.
Antimicrobial resistance (AMR) is a major threat to global public health that continues to grow owing to selective pressure caused by the use and overuse of antimicrobial drugs. Resistance spread by plasmids is of special concern, as they can mediate a wide distribution of AMR genes, including those encoding extended-spectrum -lactamases (ESBLs). The CTX-M family of ESBLs has rapidly spread worldwide, playing a large role in the declining effectiveness of third-generation cephalosporins.
View Article and Find Full Text PDFInflamm Bowel Dis
January 2025
Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, 5th Floor Cal Wenzel Precision Health Building, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada.
Background: Historically, randomized controlled trials (RCTs) have been criticized for being poorly generalizable to patients with ulcerative colitis (UC) evaluated in routine care. We aimed to evaluate the proportion of patients with UC starting an advanced therapy who would be eligible to participate in phase 3 registrational UC RCTs.
Methods: We conducted a retrospective cohort analysis of UC patients starting vedolizumab, ustekinumab, or tofacitinib at 2 IBD clinics at the University of Calgary.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!